A possibly overlooked side effect of orlistat: Gastroesophageal reflux disease

Journal of the National Medical Association

Volumn 100, Issue 10, 2008, Pages 1207-

  Buyukhatipoglu, Hakan ^a  

^a GAZIANTEP UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

TETRAHYDROLIPSTATIN;

FECES INCONTINENCE; FLATULENCE; GASTROESOPHAGEAL REFLUX; HUMAN; LETTER; MUSCLE CRAMP; OBESITY; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT MONITORING; PHYSICIAN; PRIORITY JOURNAL;

EID: 55349110006     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-9684(15)31487-5     Document Type: Editorial

References (2)

1. Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care. 1998;21:1288-1294.
2. El-Serag HB, Ergun GA, Pandolfino J, et al. Obesity increases oesophageal acid exposure. Gut. 2007;56:749-755.